One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists are antidiabetic drugs that possess a suppressive effect on the progression of atherosclerosis, and it has been thought that their anti-inflammatory effect is involved in their effect, but the detailed mechanism was unknown. Recently, Ben Nasr and colleagues have proposed easily understood mechanism for the anti-inflammatory effect of GLP-1 receptor agonists. They discovered that some normal T cells express GLP-1 receptors on their cell membranes and showed that GLP-1 has an inhibitory effect on T-cell function.
Authors
- Hirotaka Watada (ORCID: https://orcid.org/0000-0001-5961-1816)
Institutions
- Juntendo University (JP)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1111/jdi.14346
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.07
Funders
- Eli Lilly and Company
- Abbott Japan
- Kowa Company
- Boehringer Ingelheim Japan
- Novo Nordisk
- MSD K.K.
- Eli Lilly Japan
- Bayer Yakuhin
- Novo Nordisk Pharma
- Daiichi Sankyo Europe